OR WAIT 15 SECS
© 2020 MJH Life Sciences and BioPharm International. All rights reserved.
© 2020 MJH Life Sciences™ and BioPharm International. All rights reserved.
Automation, digitalization, and supply-chain strategies help mitigate vulnerabilities.
UK approves emergency use for Pfizer/BioNTech vaccine; industry ups manufacturing, awaits FDA EUA decisions.
December 02, 2020
The grant will support the advancement of glycoengineering technology for plant-derived proteins developed by a University of Alberta scientist partnered with PlantForm.
The investment will expand and upgrade manufacturing capacity and technology for pre-fillable syringes and will also includes a new manufacturing facility in Europe.
A holistic approach to validation and quality assurance is essential.
Establishing an automated inline dilution system can potentially ease bottlenecking delays resulting from higher upstream yields.
Viral clearance processes and guidance must evolve along with newer biotherapeutic modalities.
MHRA has granted a temporary authorization for emergency use to Pfizer and BioNTech for the mRNA vaccine against COVID-19.
December 01, 2020
Scaling needs for potential COVID-19 vaccines depend not only on capacity, but also on supply chain challenges and technological hurdles.
After a difficult year, biopharma science delivers promising results.
The expansion will include new suites for the development and clinical manufacturing of drug product intermediates and drug products and cGMP suites for early-phase cGMP manufacture.
Moderna has filed for authorization for its COVID-19 vaccine candidate, which has shown high efficacy and safety in a Phase III trial.